<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909129</url>
  </required_header>
  <id_info>
    <org_study_id>03-541</org_study_id>
    <nct_id>NCT00909129</nct_id>
  </id_info>
  <brief_title>Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment</brief_title>
  <acronym>DICO</acronym>
  <official_title>Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV
      and determine how these responses are affected by HCV treatment and correlates to response.
      Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment,
      and correlate this to treatment outcome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained virological response</measure>
    <time_frame>24 weeks end of treatment (EOT)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>T-cell mediated immune responses</measure>
    <time_frame>baseline to 24 weeks EOT</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>HIV-1 HCV coinfected patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 HCV coinfected patients undergoing HCV therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegylated interferon-alpha (Pegasys)</intervention_name>
    <description>Pegylated interferon-alpha 2a 180 micrograms s.c. weekly</description>
    <arm_group_label>HIV-1 HCV coinfected patients</arm_group_label>
    <other_name>Pegasys (interferon)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribavirin (COPEGUS)</intervention_name>
    <description>ribavirin bid 800-1200 mg depending on HCV genotype and body weight</description>
    <arm_group_label>HIV-1 HCV coinfected patients</arm_group_label>
    <other_name>COPEGUS (RIBAVIRIN)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 Hepatitis C coinfected adult patients

          -  Hepatitis C treatment naive

          -  Stable HIV-1 infection with or without cART

          -  &gt; 300 CD4+ cell count

        Exclusion Criteria:

          -  Decompensated liver disease

          -  Ongoing depression

          -  Ongoing drug abuse

          -  Other contraindications for interferon or ribavirin treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annette Alaeus, MD;PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases Unit, Dept of Medicine Solna, Karolinska Institutet Stockholm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital Solna</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 77</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Gonzalez VD, Falconer K, MichaÃ«lsson J, Moll M, Reichard O, Alaeus A, Sandberg JK. Expansion of CD56- NK cells in chronic HCV/HIV-1 co-infection: reversion by antiviral treatment with pegylated IFNalpha and ribavirin. Clin Immunol. 2008 Jul;128(1):46-56. doi: 10.1016/j.clim.2008.03.521. Epub 2008 May 20.</citation>
    <PMID>18495540</PMID>
  </results_reference>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2009</study_first_posted>
  <last_update_submitted>May 26, 2009</last_update_submitted>
  <last_update_submitted_qc>May 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Annette Alaeus</name_title>
    <organization>Karolinska Institutet Sweden</organization>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Immune activation</keyword>
  <keyword>HCV kinetics</keyword>
  <keyword>IP-10</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

